Cao Guo-Dong, He Xiao-Bo, Sun Qiang, Chen Sihan, Wan Ke, Xu Xin, Feng Xudong, Li Peng-Ping, Chen Bo, Xiong Mao-Ming
Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Jiangsu Key Laboratory of Biological Cancer, Cancer Institute, Xuzhou Medical University, Xuzhou, China.
Front Oncol. 2020 Sep 9;10:1786. doi: 10.3389/fonc.2020.01786. eCollection 2020.
Cancer has always been an enormous threat to human health and survival. Surgery, radiotherapy, and chemotherapy could improve the survival of cancer patients, but most patients with advanced cancer usually have a poor survival or could not afford the high cost of chemotherapy. The emergence of oncolytic viruses provided a new strategy for us to alleviate or even cure malignant tumors. An oncolytic virus can be described as a genetically engineered or naturally existing virus that can selectively replicate in cancer cells and then kill them without damaging the healthy cells. There have been many kinds of oncolytic viruses, such as herpes simplex virus, adenovirus, and Coxsackievirus. Moreover, they have different clinical applications in cancer treatment. This review focused on the clinical application of oncolytic virus and predicted the prospect by analyzing the advantages and disadvantages of oncolytic virotherapy.
癌症一直是对人类健康和生存的巨大威胁。手术、放疗和化疗可以提高癌症患者的生存率，但大多数晚期癌症患者通常生存情况不佳或负担不起高昂的化疗费用。溶瘤病毒的出现为我们缓解甚至治愈恶性肿瘤提供了一种新策略。溶瘤病毒可以被描述为一种基因工程改造的或天然存在的病毒，它能够在癌细胞中选择性复制，然后杀死癌细胞而不损害健康细胞。已经有多种溶瘤病毒，如单纯疱疹病毒、腺病毒和柯萨奇病毒。此外，它们在癌症治疗中有不同的临床应用。本文综述聚焦于溶瘤病毒的临床应用，并通过分析溶瘤病毒疗法的优缺点来预测其前景。
